About Our Practice

The purpose of this randomized study is to compare the safety and effectiveness of the Amulet device compared to non-vitamin K antagonist oral anticoagulants (NOACs) for ischemic stroke reduction. Patients will be randomized 50:50 to either receive the Amulet device or receive NOAC therapy.

The Amulet device is approved in some countries outside of the US but is an investigational device in the US.

The purpose of this research is to evaluate the safety and effectiveness of the Adagio Medical vCLAS™Cryoablation System (Adagio System) for the treatment of a heart arrhythmia called Ventricular Tachycardia (VT). It is enrolling patients who are scheduled to undergo cardiac ablation to treat the VT. While the FDA has approved the clinical use of this device in a pre-market investigational device exemption (IDE) study, the device has not been approved by the FDA for commercial use in the US.

This study aims to recruit patients undergoing a pulse field ablation procedure with the VARIPULSE catheter system.

Eligible subjects will be randomized to either receive the shunt procedure or not. Those who receive the shunt procedure will be followed for 5 years. Subjects in the control group will also have the opportunity to receive the procedure after the last enrolled patient has completed a 12 month post-procedure follow up.

AtriCure’s ISOLATOR® Synergy Surgical Ablation System has been cleared under the 510(k) process by the United States Food and Drug Administration (FDA) to ablate the heart to treat cardiac arrhythmias in patients undergoing open heart surgery. It is currently in commercial use in the US and various European countries however for the purposes of this trial will be labeled for Investigational Use Only.

This study will enroll patients who have been diagnosed with symptomatic Paroxysmal Atrial Fibrillation (PAF) and have decided to undergo cardiac ablation. The purpose of this research study is to provide information about the safety and long-term effectiveness of the BWI OMNYPULSE™ Pulsed Field Ablation (PFA) Platform, consisting of the TRUPULSE™ Generator and OMNYPULSE™ Catheter used in conjunction with the CARTO®3 System with the VISITAG SURPOINT™Module PF Index to treat symptomatic PAF. The BWI OMNYPULSE™ PFA Platform is an investigational device that has not been approved by the FDA.

The primary objective of this randomized study is to determine if LAA closure with the Watchman FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs). The Watchman FLX device has been approved by the FDA but is considered investigational for this study.

This study is currently in follow-up only and is not enrolling new patients.

This study will enroll patients who have been implanted or will be implanted with a WATCHMAN  FLX™ Pro Device. The WATCHMAN FLX™ Pro device is approved for commercial use in the United States and is a newly FDA approved version of the previous device called WATCHMAN  FLX™ Device.

This study is observational and will collect and analyze clinical information on patients who receive the WATCHMAN  FLX™ Pro device

This study is currently in follow-up only and is not enrolling new patients

Participants will be randomized to either receive standard PVI and posterior wall ablation in the control group, or PVI and EGF-identified ablation as the treatment group. The OptiMap Catheter system will be used to provide EGF-identified regions for ablation

This study recruits patients undergoing a repeat ablation procedure after a recurrence of PersAF, with enrollment lasting approximately 12 months.

This investigational study aims to understand the most effective treatment plan after a patient receives a WATCHMAN FLX Pro device implant. A WATCHMAN device is commonly used as a preventative measure for patients with atrial fibrillation, to reduce their risk of developing thromboembolism and stroke.  Typically, this condition is treated using stroke prevention drug therapies. However, commonly used drugs. such as Warfarin, have been known to pose a risk for bleeding complications. Patients who receive a Watchman implant, however, have a significantly lower rate of stroke and bleeding. 

Participants enrolled in this study will be randomly assigned to either receive drug therapy or DAPT treatment after their implant procedure. Patients will be monitored for one year post implant, with periodic imaging and testing done to assess the patient’s health.

This is a registry for patients undergoing an ablation using the FDA approved Farapulse system. The purpose of this Registry is to learn more about the outcomes for patients who receive an ablation using the Farapulse™ Pulsed Field Ablation System for the treatment for Paroxysmal Atrial Fibrillation (PAF), Persistent (PsAF) Atrial Fibrillation, and Long-Standing Persistent Atrial Fibrillation (LSPsAF).

The WiSE System delivers leadless LV endocardial pacing for biventricular pacing in Cardiac Resynchronization Therapy (CRT). Transthoracic echocardiography (TTE) is currently used in pre-procedure screening. While effective in many cases, TTE imaging has its limitations, as it is highly operator dependent, and can be impacted by factors such as patient BMI, position of the lungs during respiration, and patient posture. Alternatively, computed tomography (CT) offers high-resolution, reproducible imaging of thoracic anatomy and may provide more reliable visualization of rib spacing, lung position, and left ventricular wall morphology.

Participants who enroll in the study will have previously undergone a CT scan, and will receive a TTE.

The purpose of this post-approval study (PAS) is to evaluate the safety of long-term use of the OPTIMIZER Smart and CCM therapy. The study will also evaluate the effects of CCM therapy on your quality of life and HF symptoms.

Patients with symptomatic paroxysmal AF (PAF) and Persistent AF (PsAF) may be eligible to enroll in this study.

This study will enroll patients who are scheduled to receive a left atrial appendage (LAA) closure device. The purpose of this research study is to compare the safety and effectiveness of the Laminar LAA Closure System as compared to a commercially available LAA closure device to close off the LAA to eliminate a potential source of blood clots. The study will be randomized into one of two groups by a computer. The device is experimental, which means it has not been approved by the Food and Drug Administration (FDA) for commercial sale.

Participants in this study are scheduled to have a cryoablation procedure using the Medtronic Arctic Front™ System or Freezor™MAX Family of Cardiac Cryoablation Catheters (Arctic Front™) for the treatment of your persistent atrial fibrillation (AF). This type of procedure targets cardiac tissue that is causing your AF in order to freeze and destroy the abnormal tissue. The purpose of this study is to describe clinical performance and safety data in persistent AF patients treated with the Arctic Front™ and Freezor™MAX Families of Cardiac Cryoablation Catheters, which are approved by the U.S. Food and Drug Administration (FDA).

A subset of participants will receive pre- and post- procedural magnetic resonance imaging (MRI) to evaluate the incidence of silent cerebral lesions and events after their procedure.

Patients with symptomatic paroxysmal atrial fibrillation who are scheduled to undergo an ablation may qualify for this study.

The purpose of this study is to provide information about the safety and long-term effectiveness of the BWI (Biosense Webster) irreversible electroporation (IRE) ablation system consisting of the TRUPULSE™Generator and VARIPULSE™Catheter. It will enroll patients who are scheduled to undergo an atrial fibrillation (AF) ablation to treat AF. 

The BWI IRE Ablation system uses a new type of energy source called pulsed field, which uses ultra-rapid electrical fields on the heart muscle to cause IRE to treat AF. The system is investigational and has not been approved by the Food and Drug Administration (FDA). 

The purpose of this research study is to answer specific questions about the accuracy of an artificial intelligence (AI) Software as Medical Device (SaMD) which is intended to compute ejection fraction (EF) severity from ambulatory ECG wearable patch (a patch to be used while walking around). The AI software is used to process previously acquired continuous ECG data produced by the FDA cleared Peerbridge Cor® ECG Wearable Monitor to aid in screening for left ventricle EF severity classification. 

The Peerbridge COR® ECG wearable devices that are being used in this study have been cleared by the United States Food and Drug Administration (FDA). However, the use of the device to estimate EF is considered investigational.

The purpose of this study is to evaluate the impact of anxiety on the heart tissue changes leading to non-PV triggers and LA scar in patients after AF ablation.

Participants will wear the Skiin chest band and collect their ECG for 14 days. They will also record any symptoms they experience during the monitoring period, such as palpitations, shortness of breath, and fatigue. The data collected in this study will be used to develop new algorithms and patient monitoring tools to detect and predict cardiovascular health problems.

This study will enroll patients who have had or will be undergoing a left atrial appendage occlusion (LAAO) procedure. A rare but known complication is the development of a clot on the LAAO device. This study will evaluate blood samples to identify blood protein biomarkers that could predict clot formation. The purpose of this study is to examine the association of blood-proteins with LAAO-related clot.